What is Entyvio?

Entyvio (vedolizumab) is a first-in-class, gut-selective biologic treatment for moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.1

Licensed Indications

Ulcerative Colitis

Ulcerative Colitis

Entyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNFα) antagonist.1

UC Clinical Data

Crohn’s Disease

Crohn’s Disease

Entyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have an inadequate response with, lost response to, or were intolerant to either conventional therapy or TNFα antagonist.1

CD Clinical Data

Entyvio Mode of Action

Vedolizumab is a gut-selective immunosuppressive biologic drug. It is a humanised monoclonal antibody integrin antagonist. It binds specifically to the alpha-4, beta-7 (α4β7) integrin, which is preferentially expressed on gut-homing T-helper lymphocytes.1

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Any adverse events observed following the prescription of Entyvio should be reported. In the United Kingdom, adverse event reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.